Teva Pharmaceutical Industries Ltd
TEVA
NYSE
Pharmaceuticals
$34.71
USD
+3.04 (+9.60%)
At close: Jul 29, 2026, 4:00 PM EDT
Market Cap $36.24B
Volume 17.8M
Revenue
$17.35B
TTM
+4.4%
YoY
Gross Margin
52%
TTM
+5.9%
YoY
Net Income
$1.57B
TTM
+218.8%
YoY
Operating Cash Flow
$1.71B
TTM
+35.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 3,891.0 | 4,176.0 | 4,480.0 | 4,711.0 | 3,982.0 |
YoY Growth | +1.9% | +0.3% | +3.4% | +11.4% | +2.3% |
Cost of Revenue | 2,014.0 | 2,074.0 | 2,176.0 | 2,056.0 | 2,011.0 |
Gross Profit | 1,877.0 | 2,102.0 | 2,304.0 | 2,655.0 | 1,971.0 |
Selling, General & Administrative | 919.0 | 959.0 | 973.0 | 1,120.0 | 1,000.0 |
Other Operating Expenses | 190.0 | 440.0 | 193.0 | 969.0 | 97.0 |
Total Operating Expenses | 1,356.0 | 1,643.0 | 1,422.0 | 2,356.0 | 1,319.0 |
Operating Income | 521.0 | 459.0 | 882.0 | 299.0 | 652.0 |
EBITDA | 950.0 | 1,150.0 | 1,317.0 | 1,524.0 | 997.0 |
Other Income / Expense | -225.0 | -256.0 | -236.0 | -219.0 | -215.0 |
Total Other Income / Expense | -225.0 | -256.0 | -236.0 | -219.0 | -215.0 |
Income Before Income Taxes | 296.0 | 203.0 | 646.0 | 80.0 | 437.0 |
Income Taxes | 74.0 | -78.0 | 214.0 | -390.0 | 67.0 |
Net Income | 220.0 | 283.0 | 434.0 | 481.0 | 369.0 |
Consolidated Net Income / Loss | 222.0 | 282.0 | 434.0 | 481.0 | 370.0 |
Net Income Attributable to Common Shareholders | 216.0 | 282.0 | 433.0 | 480.0 | 370.0 |
Basic EPS | $0.19 | $0.25 | $0.38 | $0.42 | $0.32 |
Diluted EPS | $0.18 | $0.24 | $0.37 | $0.41 | $0.31 |
Basic Shares Outstanding | 1,138.0M | 1,147.0M | 1,147.0M | 1,145.0M | 1,156.0M |
Diluted Shares Outstanding | 1,159.0M | 1,161.0M | 1,164.0M | 1,163.0M | 1,179.0M |